Incretin Management in Type 2 Diabetes
In this educational hub ‘Incretin Management in Type 2 Diabetes’ the faculty present the importance of screening and early intensification for better glycaemic control and improved vascular and mortality outcomes in type 2 diabetes.
In this series of CME accredited videos and downloadable summaries, leading global experts will guide you through how the incretin system works, what happens to it in type 2 diabetes and how to optimise the use of incretin-based agents for better patient outcomes.
This programme is intended to educate:
- Primary care physicians (PCPs)/ General Practitioners (GPs)
The overall programme, ‘Incretin Management in Type 2 Diabetes’’, endeavours to best address the following learning objectives:
- Recall the components of the ‘ominous octet’ & how they contribute to T2DM development
- Identify underlying facets of clinical inertia in T2DM care
- Describe how early adoption of intensive glycaemic control leads to better outcomes in T2DM
- Recall efficacy & the mode of action of various incretin-based treatments
- Adopt an early, intensive glucose-lowering strategy in appropriate individuals
- Select appropriate incretin treatment & dosing regimens according to patient profiles
- Identify individuals likely to gain cardiovascular benefit from GLP-1RAs
- Select appropriate actions following adverse events from incretin-based treatments
In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
This programme is supported by an unrestricted educational grant by Novo Nordisk A/S. The scientific programme has not been influenced in any way by the sponsors.
R-CME DISCLAIMER / TERMS & CONDITIONS
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
The session of ‘Incretin Management in Type 2 Diabetes’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
INSTRUCTIONS TO PARTICIPANTS
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied. Users must read, watch the videos and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Dr Mikhail Kosiborod
Saint Luke’s Mid America Heart Institute, Kansas City, US
Dr Silvio Inzucchi
Yale School of Medicine, New Haven, US
Dr Kamlesh Khunti
University of Leicester, UK
Dr Sarah Davies
Cardiff and Vale University Health, UK
Somerset NHS Foundation Trust, UK
- 1.00 European Board for Accreditation in Cardiology (EBAC)